This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
21 Nov 2011

Eisai Inks Pact with Novartis Pharma for COPD Therapies

The new co-promotion agreement is a partnership of mutual commitment between Eisai and Novartis Pharma.

Eisai Co. Ltd has signed a Japan co-promotion agreement with Novartis Pharma K.K. for three Novartis Pharma therapies for chronic obstructive pulmonary disease (COPD).

 

The new co-promotion agreement is a partnership of mutual commitment between Eisai and Novartis Pharma.

 

The therapies include Onbrez Inhalation Capsules 150 mcg (indacaterol maleate), which were launched in Japan on September 20, 2011, and, if approved, the investigational drugs NVA237 (glycopyrronium bromide) and QVA149 (fixed-dose combination of indacaterol maleate and glycopyrronium bromide), both of which are currently in Phase III development.

 

Based on this agreement, the two companies will begin co-promotin

Related News